The 1st Psoriasis Symposium, organised by the Psoriasis Association of Bosnia and Herzegovina in collaboration with the Skin Inflammation & Psoriasis International Network (SPIN), the International Society of Dermatology and the European Academy of Dermatology and Venerology, was held in Sarajevo on 13-15 October 2017.
The Symposium was intended to provide delegates with the latest research and facts on diagnoses and genetics of psoriasis and psoriatic arthritis, long-term treatment with available therapies and treatments in development.
Approximately 200 participants and 40 guests from 22 countries across three continents participated in the Symposium.
The Symposium’s scientific programme included lectures by 26 international invited speakers, with the aim of presenting contemporary achievements in psoriasis and exchanging experiences.
There were 46 lectures and 21 poster presentations as well as 5 sponsored satellite symposia.
The main topics of the Symposium were:
- Immune system and psoriatic disease
- Psoriasis as a systemic disease
- Psoriasis in childhood and pregnancy
- Clinical and diagnostic characteristics of psoriasis and psoriatic arthritis
- Psoriasis therapy: from conventional therapies to biological drugs
- Free themes
As a partner organization, SPIN organized a session during this meeting.
Following the welcome and introductory speeches of SPIN Chair Professor Jo Lambert, lectures were held by the members of the SPIN Scientific Committee:
- Prof. Nejib Doss, Tunisia: Nail psoriasis: differential diagnosis
- Prof. Christopher Griffiths, UK: Systems medicine and psoriasis management
- Prof. Romana Ceovoc, Croatia: Topical treatments and phototherapy in the era of biologics
- Prof. Thomas A. Luger, Germany: Novel therapies for psoriasis: where are we going?
- Prof. Jo Lambert, Belgium: Tailored prescribing of biologicals: a challenge for the near future.
That event was also marked by the celebration of World Psoriasis Day - a day for awareness and advocacy for all people living with psoriasis and psoriatic arthritis around the world!
Rich cultural and social programs and the unique multicultural spirit and historical heritage of Sarajevo city have contributed to the good mood of all participants wishing to meet again and to exchange some new experiences.
SPIN Presentation
Recent news
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
- 2019/04/17 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P et al.
JAK-inhibitors in dermatology: current evidence and future applications.
J Dermatolog Treat.
2019 Nov , 30, (7):648-658.
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such (...)
see on pubmed
Patient preferences for attributes of topical anti-psoriatic medicines.
Vasconcelos V et al.
Patient preferences for attributes of topical anti-psoriatic medicines.
J Dermatolog Treat.
2019 Nov , 30, (7):659-663.
Patient preferences should be considered when prescribing topical treatments to drive up adherence and improve clinical outcomes. The aim of this work was to identify the most important attributes of topical medicines for psoriasis treatment in the patients' view, and explore the sociodemographic and clinical determinants of these preferences. A questionnaire for the evaluation of the relevancy given to specific attributes of topical medicines used for psoriasis treatment was developed (...)
see on pubmed
Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation.
Redox Rep..
2019 Dec , 24, (1):70-74.
To unveil the role of SIRT1 in limiting oxidative stress in psoriasis and to further discuss the therapeutic prospects of salidroside in psoriasis. Literature from 2002 to 2019 was searched with "psoriasis", "oxidative stress", "SIRT1", "salidroside" as the key words. Then, Oxidative stress in psoriasis and the role of SIRT1 were summarized and the potential role of salidroside in the disease was speculated. Oxidative stress might contribute to the pathogenesis of psoriasis. High levels (...)
see on pubmed
on Atopic Dermatitis
A case of infective endocarditis associated with atopic dermatitis perioperatively treated with dupilumab.
J Dermatolog Treat.
2019 Nov , 30, (7):674-676.
Several case reports and reviews support a relationship between atopic dermatitis (AD) and infective endocarditis (IE). Here, we present a case of severe AD suspected of causing IE. A 21-year-old man with severe AD was admitted to our hospital due to unidentified fever, syncope, and headache. He was diagnosed with IE with cerebral embolism and mitral regurgitation. Before elective cardiac surgery, he was subcutaneously administered dupilumab for 2 months to control AD. Dupilumab improved (...)
see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
Choi EJ et al.
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem.
2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)
see on pubmed
Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Artif Cells Nanomed Biotechnol.
2019 Dec , 47, (1):3540-3547.
Allergen-specific immunotherapy is widely used for allergic rhinitis and asthma treatment worldwide. This study explored the efficacy and safety of sublingual immunotherapy (SLIT) with the extracts of ( Drops) on house dust mites (HDM)-induced atopic dermatitis (AD). 239 patients with HDM-induced AD were recruited and exposure to a multi-centre, randomized, double-blind, and placebo-controlled clinical trials for 36 weeks, which were randomly divided into placebo and sublingual Drops (...)
see on pubmed
